A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cyst

    Project: Other project

    Project Details

    StatusActive
    Effective start/end date6/11/21 → 6/10/26

    Funding

    • Janssen Pharmaceutical Research & Develo: $65,337.54